Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com 3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com 4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com 4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com 4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com 4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com 4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com 4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com 4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com 5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com 5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com 5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@Primary_Immune 5 years ago
The First #Cannabis-Based Drug (For #Epilepsy) Just Gained FDA Approval; The Remarkable Story Behind the Story https://www.cincinnati.com/story/news/2018/06/27/cincinnati-test-site-weed-drug-fda-has-just-approved/732043002/ #ITRTG #BigData #science #technology #genetics #SNRTG #biotech #Dravet #marijuana #MedicalMarijuana #inspiration #RareDisease #SciComm @apsaker https://t.co/QcweE89RhI
@xconomy.com 5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines